AstraZeneca PLC (AZN) Earnings Call Analysis

NASDAQ · Unknown · Unknown

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
AstraZeneca (AZN) Q2 2026: Oncology Revenue Jumps 15% as Pipeline Diversifies Beyond LOE Headwinds
July 27, 2026
24
AstraZeneca (AZN) Q4 2025: Oncology Surges 17% as Pipeline Catalysts Drive $10B+ Peak Revenue Potential
June 15, 2026
19
AstraZeneca (AZN) Q1 2026: Oncology Surges 16% as Pipeline Readouts Set $10B+ Peak Revenue Path
April 30, 2026
23
AstraZeneca (AZN) Q3 2025: Oncology Surges 16% as $10B Pipeline Readouts Shape 2026 Trajectory
November 11, 2025
24
AstraZeneca (AZN) Q2 2025: R&D Spend Climbs to 23% of Revenue as Pipeline De-Risks $80B 2030 Target
July 29, 2025
23
AstraZeneca (AZN) Q1 2025: Broad-Based 10% Revenue Growth Anchored by Pipeline Momentum and Operational Resilience
June 10, 2025
AstraZeneca (AZN) Q3 2024: U.S. Investment Rises $3.5B as Global Portfolio Drives 21% Growth
November 12, 2024
AstraZeneca (AZN) Q2 2024: Oncology Revenue Climbs 22%, Fueling Guidance Upgrade and Pipeline Ambition
July 25, 2024
AstraZeneca (AZN) Q1 2024: Oncology Revenue Surges 26% as Pipeline and Portfolio Scale Drive Multi-Year Growth
April 25, 2024
AstraZeneca (AZN) Q4 2023: Oncology and Rare Disease Drive 21% and 12% Growth, Setting Stage for Next Decade
February 08, 2024
25
AstraZeneca (AZN) Q3 2023: Non-COVID Medicines Surge 15% as Pipeline Expansion Reshapes Growth Outlook
November 15, 2023

Browse all companies